Double‐blind, vehicle‐controlled clinical investigation of peptide OS ‐01 for skin rejuvenation
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16242 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Alessandra Zonari und 6 weiteren Autor:innen. Beteiligte Einrichtung: OneSkin Inc., San Francisco, California, USA. Hauptthemen laut MEDLINE: Skin Aging, Rejuvenation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Senescent cells contribute to age‐related tissue deterioration, including the skin, which plays important roles in overall health and social interactions. This study aimed to assess the effects of the senotherapeutic peptide, OS‐01 (a.k.a. Pep 14), on skin.
Methods
A 12‐week split‐face, double‐blinded, vehicle‐controlled study involving 22 participants was conducted. The OS‐01‐containing formulation was applied to one side of the face, while the other side received an identical control formulation lacking the peptide. Skin characteristics were assessed using instrumental measurements, expert clinical grading, and subjective questionnaires.
Results
Results showed that the OS‐01 formulation significantly improved one aspect of skin barrier function, as evidenced by reduced trans‐epidermal water loss compared to both baseline and vehicle control. Expert grading and Antera 3D image analysis revealed a reduction in wrinkle appearance and indentation in the periorbital area, and improved skin texture and radiance on both sides of the face, with the OS‐01‐containing formulation demonstrating superior results. Participants also perceived improvements in skin hydration, smoothness, radiance, and overall appearance.
Conclusion
The findings suggest that the OS‐01 formulation promotes skin health by strengthening the skin barrier, protecting against dehydration, reducing the appearance of wrinkles, and improving skin texture and radiance. These effects are likely attributed to the senotherapeutic properties of OS‐01 in reducing cellular senescence and its associated detrimental effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- OneSkin Inc., San Francisco, California, USA.
- Bioinformatics and Computational Biology Lab, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
- Genomic Sciences and Biotechnology Program, Catholic University of Brasilia, Brasília, Brazil.
- Laboratory of Interdisciplinary Biosciences, Faculty of Medicine, University of Brasília, Brasília, Brazil.
Zitieren
APA
Zonari, A., Brace, L. E., Harder, N. H. O., Harker, C., Oliveira, C. R., Boroni, M., & Carvalho, J. L. (2024). Double‐blind, vehicle‐controlled clinical investigation of peptide OS ‐01 for skin rejuvenation. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16242
Vancouver
Zonari A, Brace LE, Harder NHO, Harker C, Oliveira CR, Boroni M, et al. Double‐blind, vehicle‐controlled clinical investigation of peptide OS ‐01 for skin rejuvenation. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16242
BibTeX
@article{Zonari2024,
author = {Zonari, Alessandra and Brace, Lear E and Harder, Nathaniel H O and Harker, Claire and Oliveira, Carolina R and Boroni, Mariana and Carvalho, Juliana L},
title = {Double‐blind, vehicle‐controlled clinical investigation of peptide OS ‐01 for skin rejuvenation},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16242}
}
EUVIMED